| Literature DB >> 34512170 |
Wenjing Pang1,2, Weiyan Yao3, Xin Dai3, Aisen Zhang4,5, Lidan Hou1,2, Lei Wang1,2, Yu Wang1,2, Xin Huang1,2, Xiangjun Meng1,2, Lei Li1,2.
Abstract
New-onset diabetes mellitus has a rough correlation with pancreatic cancer (PaC), but the underlying mechanism remains unclear. This study aimed to explore the exosomal microRNAs and their potential role in PaC-induced β-cell dysfunction. The pancreatic β cells were treated with isolated exosomes from PaC cell lines, SW1990 and BxPC-3, before measuring the glucose-stimulated insulin secretion (GSIS), validating that SW1990 and BxPC-3 might disrupt GSIS of both β cell line MIN6 and primary mouse pancreatic islets. The difference in expression profiles between exosomes and exosome-free medium of PaC cell lines was further defined, revealing that miR-19a secreted by PaC cells might be an important signaling molecule in this process. Furthermore, adenylyl cyclase 1 (Adcy1) and exchange protein directly activated by cAMP 2 (Epac2) were verified as the direct targets of exogenous miR-19a, which was involved in insulin secretion. These results indicated that exosomes might be an important mediator in the pathogenesis of PaC-DM, and miR-19a might be the effector molecule. The findings shed light on the pathogenesis of PaC-DM. © The author(s).Entities:
Keywords: exosome; miR-19a; pancreatic neoplasm; β cell dysfunction
Mesh:
Substances:
Year: 2021 PMID: 34512170 PMCID: PMC8416731 DOI: 10.7150/ijbs.56271
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Figure 1(A) GSIS assay in supernatants or exosomes derived from PaC treated-MIN6. (B) GSIS assay in supernatants or exosomes derived from PaC treated-primary islets. (C) Quantitative RT-PCR analysis of miRNA expression levels in exosomes and exosome-free supernatant of PaC cells. (D) Relative expression level of miRNAs in MIN6 cells treated with PaC cell exosomes. (E) Impact of miR-19a on the GSIS assay in MIN6 cells. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2(A) Predicted free energy value of hybrid of Adcy1 3'-UTR and miR-19a. (B and C) Western blot analysis of Adcy1 protein levels in MIN6 cells treated with pre-miR-19a or anti-miR-19a. (B) Representative image. (C) Quantitative analysis. (D) Quantitative RT-PCR analysis of Adcy1 mRNA levels in MIN6 cells treated with pre-miR-19a or anti-miR-19a. (E) Luciferase reporters containing wild-type (WT) or mutant (MUT) miR-19a-binding sites in Adcy1 3'-UTR were co-transfected into MIN6 cells with pre-miR-19a or anti-miR-19a. The results were calculated as the ratio of luciferase activity in pre-miR-19a- or anti-miR-19a-transfected cells normalized to control cells. (F and G) Adcy1 overexpression plasmids were transfected into MIN6 cells with pre-miR-19a or pre-miR-control. The results were calculated as the ratio of protein expression levels normalized to corresponding controls. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3(A) Predicted free energy value of the hybrid of Epac2 3'-UTR and miR-19a. (B and C) Western blot analysis of Epac2 protein levels in MIN6 cells treated with pre-miR-19a or anti-miR-19a. (B) Representative image. (C) Quantitative analysis. (D) Quantitative RT-PCR analysis of Epac2 mRNA levels in MIN6 cells treated with pre-miR-19a or anti-miR-19a. (E) Luciferase reporters containing wild-type (WT) or mutant (MUT) miR-19a-binding sites in the Epac2 3'-UTR were co-transfected into MIN6 cells with pre-miR-19a or anti-miR-19a. The results were calculated as the ratio of luciferase activity in pre-miR-19a- or anti-miR-19a-transfected cells normalized to control cells. (F and G) Epac2 overexpression plasmids were transfected into MIN6 cells with pre-miR-19a or pre-miR-control. The results were calculated as the ratio of protein expression levels normalized to corresponding controls. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 4(A-D) Western blot analysis of Adcy1 and Epac2 protein levels in primary islets treated with exosomes derived from PaC cells. (A and B) Representative image. (C and D) Quantitative analysis. (E-H) Western blot analysis of Adcy1 protein levels in islets treated with miR-19a-deficient exosomes from SW1990 (E and G) or BxPC-3 (F and H) cells and controls. (E and F) Representative image. (G and H) Quantitative analysis. (I-L) Western blot analysis of Epac2 protein levels in MIN6 cells treated with miR-19a-deficient exosomes from SW1990 (I and K) or BxPC-3 (J and L) cells and controls. I and J: Representative image; K and L: quantitative analysis. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 5(A) cAMP expression level in MIN6 cells treated with the miR-19a-deficient PaC exosomes and control PaC exosomes. (B) Ca2+ concentration in MIN6 cells treated with miR-19a-deficient PaC exosomes and control PaC exosomes. (C) GSIS assay in MIN6 cells co-transfected with pre-miR-19a, Adcy1 OE plasmid, and corresponding controls. (D) cAMP expression level in MIN6 cells co-transfected with pre-miR-19a, Adcy1 OE plasmid, and corresponding controls. (E) Ca2+ concentration in MIN6 cells co-transfected with pre-miR-19a, Adcy1 OE plasmid, and corresponding controls. (F) GSIS assay in MIN6 cells co-transfected with pre-miR-19a, Epac2 OE plasmid, and corresponding controls. (G) Insulin mRNA expression levels in MIN6 cells co-transfected with pre-miR-19a, Epac2 OE plasmid, and corresponding controls. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 6(A) Representative image of the PAN02 cells stably transfected by fluorescence-labelled lentivirus. (B) Quantitative analysis of miR-19a between PAN02 and lentivirus-treated PAN02. (C) Flow chart of the in vivo experiment design. Nude mice were first implanted orthotopically with miR-19a-deficient PAN02, untreated PAN02 (2.5×106 cells per mouse) or PBS as controls. Then, each mouse was inspected every week to 30 days. Before mice sacrifice and samples collection, IPGTT and ITT tests were performed in 2 separated days. (D) The images of the orthotopic tumors. (E) The verification of the orthotopic tumors by HE staining. (F) IPGTT tests. (G) ITT tests. (H) Western blot analysis of Adcy1 and Epac2 protein levels in primary islets of the 3 groups. (I) Relative Adcy1 and Epac2 mRNA expression levels in primary islets of the 3 groups. (J) Relative miR-19a expression levels in primary islets of the 3 groups. *P < 0.05; **P < 0.01; ***P < 0.001.